Advanced search
Publication Cover
Journal of Medical Economics Volume 17, 2014 - Issue 12
Submit an article Journal homepage
689
Views
13
CrossRef citations to date
0
Altmetric
Gastroenterology: Original articles

Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost

Neeta TandonJanssen Scientific Affairs, LLC Titusville, NJUSACorrespondence[email protected]
,
Luis A. BalartTulane University Health Sciences Center New Orleans, LAUSA
,
François LalibertéGroupe d’analyse Ltée, Montréal, QCCanada
,
Dominic PilonGroupe d’analyse Ltée, Montréal, QCCanada
,
Patrick LefebvreGroupe d’analyse Ltée, Montréal, QCCanada
,
Guillaume GermainGroupe d’analyse Ltée, Montréal, QCCanada
&
Avinash PrabhakarJanssen Scientific Affairs, LLC Titusville, NJUSA
 show all
Pages 862-871 | Accepted 09 Sep 2014, Published online: 08 Oct 2014

Citations (13)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Scott J. Johnson, Hélène Parisé, Suchin Virabhak, Ivana Filipovic, Jennifer C. Samp & Derek Misurski. (2016) Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection. Journal of Medical Economics 19:10, pages 983-994.
Read now
Joyce LaMori, Neeta Tandon, François Laliberté, Guillaume Germain, Dominic Pilon, Patrick Lefebvre & Avinash Prabhakar. (2016) Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C. Journal of Medical Economics 19:4, pages 364-373.
Read now
Neeta Tandon, Luis A. Balart, François Laliberté, Dominic Pilon, Patrick Lefebvre, Guillaume Germain & Avinash Prabhakar. (2015) Reply: Essential need for research in hepatitis C. Journal of Medical Economics 18:7, pages 514-515.
Read now
J. S. McCombs. (2015) Essential need for research in hepatitis C. Journal of Medical Economics 18:7, pages 512-513.
Read now

Articles from other publishers (9)

T. Joseph MattinglyIIII, Bryan L. Love & Bilal Khokhar. (2020) Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review. PharmacoEconomics 38:9, pages 927-939.
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbilidad, medicación concomitante, uso de recursos y costes sanitarios asociados a los pacientes portadores del virus de la hepatitis C crónica en España. Gastroenterología y Hepatología 41:4, pages 234-244.
Crossref
Antoni Sicras-Mainar, Ruth Navarro-Artieda & Marc Sáez-Zafra. (2018) Comorbidity, concomitant medication, use of resources and healthcare costs associated with chronic hepatitis C virus carriers in Spain. Gastroenterología y Hepatología (English Edition) 41:4, pages 234-244.
Crossref
Sheila A. Williams. (2018) Nursing Interventions on Medication Adherence During Hepatitis C Treatment. Gastroenterology Nursing 41:6, pages 525-531.
Crossref
Dan-Dan Bian, Hai-Yang Zhou, Shuang Liu, Mei Liu, Carol Duan, Jin-Yan Zhang, Ying-Ying Jiang, Ting Wang, Yu Chen, Zhao Wang, Su-Jun Zheng & Zhong-Ping Duan. (2017) Current treatment status and barriers for patients with chronic HCV infection in mainland China. Medicine 96:34, pages e7885.
Crossref
Andrew Kageleiry, David Samuelson, Mei Sheng Duh, Patrick Lefebvre, John Campbell & Brian G. Skotko. (2016) Out‐of‐pocket medical costs and third‐party healthcare costs for children with Down syndrome. American Journal of Medical Genetics Part A 173:3, pages 627-637.
Crossref
Hai-yang Zhou, Shuang Liu, Su-jun Zheng, Xiao-xia Peng, Yu Chen, Carol Duan, Qing-fen Zheng, Zhao Wang & Zhong-ping Duan. (2016) Coverage of different health insurance programs and medical costs associated with chronic hepatitis C infection in mainland China: a cross-sectional survey in 20 provinces. Hepatology, Medicine and Policy 1:1.
Crossref
E. H. Teshale, J. Xing, A. Moorman, S. D. Holmberg, P. R. Spradling, S. C. Gordon, L. B. Rupp, M. Lu, J. A. Boscarino, C.M. Trinacity, M. A. Schmidt & F. Xu. (2016) Higher all‐cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study ( CH e CS ), 2006–2013 . Journal of Viral Hepatitis 23:10, pages 748-754.
Crossref
Bashar M Attar. (2016) Hepatitis C virus: A time for decisions. Who should be treated and when?. World Journal of Gastrointestinal Pharmacology and Therapeutics 7:1, pages 33.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.